NeuroOne Expands Patent Portfolio with Key Approvals from US and European Patent Offices

NeuroOne Medical Technologies Corporation has significantly expanded its intellectual property portfolio with recent patent approvals from both the United States and European patent offices. The medical technology company, focused on improving surgical care for neurological disorders, received three key patent decisions that strengthen its position in the neurological device market. These developments signal important advancements in the company's technology platform and competitive positioning.

The United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application 17/860,232, titled "Probe Devices with Temperature Sensors and Related Systems and Methods." This patent covers novel electrode devices featuring at least one electrode contact and a temperature sensor, representing a significant safety enhancement for brain ablation procedures. The temperature control feature is integral to NeuroOne's OneRF Ablation System®, providing critical safety measures for patients undergoing brain ablations to treat seizures.

In Europe, the European Patent Office granted European Patent 4013481, titled "Spinal Cord Stimulation Systems, Methods, and Devices." This marks NeuroOne's first granted patent in Europe and covers innovative spinal cord stimulation devices with deployable electrode array bodies. The technology features a percutaneously placed paddle electrode designed to treat lower back pain without requiring surgical incisions, potentially improving patient outcomes and reducing procedural costs. More information about the company's technology platform can be found at https://nmtc1.com.

Additionally, the USPTO issued U.S. Patent 12,435,407, titled "Methods for Making Probe Devices and Related Devices," covering novel manufacturing methods for neural probe and spinal cord stimulation devices. This patent includes specific steps for arranging probe components and depositing electrode contact material, enhancing the company's manufacturing capabilities for thin-film electrode technologies. These patents join NeuroOne's existing portfolio of four additional issued U.S. patents, seven pending U.S. applications, and eight pending foreign applications.

Dave Rosa, chief executive officer of NeuroOne, emphasized the company's progress in expanding its robust patent portfolio and the goal to continue growing the technology platform for broader applications. The company's focus on developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation addresses various neurological disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. The expanded patent protection provides NeuroOne with stronger intellectual property rights as it continues to develop technologies that may improve patient outcomes in neurological care.